Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Improved Postmarket Compliance Requires FDA, Industry Attention – Phillips

This article was originally published in The Gray Sheet

Executive Summary

PMA sponsors should negotiate post-approval conditions with FDA prior to accepting an approval order rather than seeking changes later, CDRH Office of Device Evaluation's Philip Phillips advises
Advertisement

Related Content

CDRH Proposes Increased Transparency For Device Postapproval Studies
CDRH Proposes Increased Transparency For Device Postapproval Studies
Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman
Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman
R2 CAD Panel Conditions: Postmarket Clinical Efficacy Study, Data Reanalysis
Inamed Silicone Implant Patient Monitoring Plans Allay Rupture Concerns
Inamed Silicone Implant Patient Monitoring Plans Allay Rupture Concerns
Nellcor OxiFirst Verdict Contingent On NIH FOX Trial Results, Panel Agrees
Advertisement
UsernamePublicRestriction

Register

MT019796

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel